Jeff Passan of Yahoo! reports that the Red Sox’ use of Toradol was contrary to state law and industry guidelines. Specifically: Passan quotes Curt Schilling — and, importantly, two other sources who are not Curt Schilling — who say that the Red Sox’ trainer routinely injected it into players despite state laws which prohibit sports trainers from doing do.
Toradol, in the news recently because of Jonathan Papelbon saying that the Phillies would not let him use it, is a legal anti-inflammatory. It’s more powerful, however, and has been linked to serious side effects. Many teams use it — many also via injections from athletic trainers — but it remains controversial.
Passan reports that the methods of Toradol injection on the Red Sox weren’t, if his sources are correct, in compliance with the law. Indeed, they sounded downright furtive:
Two other sources described the same scene as Schilling: Reinold and a player stashed away in a secluded area, away from the trainers’ room, with [Red Sox trainer Mike] Reinold jabbing a needle into a player’s buttocks before a game.
Major League Baseball investigated Reinold and the Red Sox and last year issued an edict forbidding trainers from injecting players with Toradol. Whether the state gets involved and investigates depends on whether someone files a complaint. Which seems unlikely, but who knows?
According to Jorge Castillo of the Washington Post, Nationals infielder Danny Espinosa declined to attend the team’s annual Winterfest because of his dissatisfaction with management following their trade for outfielder Adam Eaton.
A source told Castillo that Espinosa’s unhappiness stemmed from a belief that the acquisition would jeopardize his starting role in 2017. With Eaton in center field, Trea Turner will likely return to his post at shortstop, leaving Espinosa out in the cold — or, as the case may be, on the bench. The move shouldn’t come as a big surprise to Espinosa, however, as Nationals’ GM Mike Rizzo spoke to the possibility of trading the infielder or reassigning him to a utility role back in early November.
Offensively, the 29-year-old had a down year in 2016, slashing just .209/.306/.378 with 24 home runs in 601 PA. Defensively, he still profiles among the top shortstops in the National League, with eight DRS (Defensive Runs Saved) and 8.3 Def (Defensive Runs Above Average) in his seventh year with the club.
Espinosa will reach free agency after the 2017 season.
The Red Sox might be trying to move the wrong pitcher, according to the Boston Globe’s Nick Cafardo. Cafardo revealed that while the Sox have been trying to market right-hander Clay Buchholz, more teams would be interested in trades involving southpaw Drew Pomeranz.
The club appears reluctant to deal Pomeranz, especially because his price tag comes in at a cool $4.7 million to Buchholz’s $13.5 million in 2017. Those who have already expressed interest in the veteran hurlers, including the Twins, Mariners and Royals, also seem put off by Buchholz’s salary requirements as he enters his 32nd year.
Health could be another factor preventing teams from jumping to make trade offers, as Cafardo quotes an AL executive who believes the “medicals on both Pomeranz and Buchholz probably aren’t that great.” Neither pitcher suffered any major injuries during the 2016 season, though Pomeranz missed just over a week of play due to forearm soreness.
Pomeranz outperformed his fellow starter in 2016, pitching to a 3.32 ERA and career-best 9.8 K/9 through 170 2/3 innings with the Padres and Red Sox. He got off to an exceptionally strong start in San Diego, where his ERA dropped to 2.47 through the first half of the year before the Padres dealt him to Boston for minor league right-hander Anderson Espinoza. Buchholz, on the other hand, struggled with a 4.78 ERA and saw a decline in both his BB/9 and K/9 rates as he worked out a career-low 1.69 K/BB through 139 1/3 innings with the Sox.